The flat core sales and declining margins confirm the emergency medicine headwind is persisting longer than anticipated. Q2 guidance implies a significant sequential improvement but still well below prior year, watch for execution on the injectables GLP-1 ramp and any further destocking commentary on the earnings call. The CEO transition adds medium-term uncertainty.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $118.55entry
- T+1 · 7mo ago +1.33%α +1.67% · $120.13
- T+5 · 6mo ago +2.06%α −0.29% · $120.99
- T+20 · 6mo ago −5.21%α −10.47% · $112.38
- T+60 · 4mo ago +16.24%α +13.18% · $137.81
Price Chart
How similar events traded
Executive Summary
AptarGroup reported Q1 2026 GAAP diluted EPS of $1.12, down 4% YoY from $1.17, and adjusted EPS of $1.19, down 8% YoY at constant currency. Reported sales rose 11% to $982.9M, but core sales were flat, and adjusted EBITDA margin contracted 150 bps to 19.2%. The company guided Q2 2026 adjusted EPS to $1.32-$1.40, below the $1.67 reported in Q2 2025, signaling continued margin pressure from emergency medicine destocking and operational disruptions.
Key Financial Metrics
Key Facts
- GAAP diluted EPS of $1.12 vs $1.17 YoY, a 4% decline
- Adjusted EPS of $1.19 vs $1.30 YoY at constant currency, down 8%
- Reported sales +11% to $982.9M, but core sales flat (0%)
- Adjusted EBITDA margin 19.2% vs 20.7% YoY, down 150 bps
- Pharma core sales declined 1%; emergency medicine destocking continued
- Beauty core sales +3%; Closures core sales flat
- Q2 2026 adjusted EPS guidance $1.32-$1.40, well below Q2 2025's $1.67
- Operating cash flow improved to $118.7M from $82.7M YoY
- Returned $131M to shareholders via buybacks and dividends
- Gael Touya named next CEO effective September 1, 2026
Financial Impact
GAAP EPS declined $0.05 YoY; adjusted EPS declined $0.11 YoY; Q2 guidance midpoint $1.36 is 18.6% below prior year's $1.67
Risk Factors
- Emergency medicine destocking may persist beyond Q2, pressuring Pharma segment
- Q2 guidance midpoint $1.36 is 18.6% below Q2 2025 actual of $1.67, implying continued earnings contraction
- Margin compression across all three segments (Pharma -150bps, Beauty -100bps, Closures -270bps)
- CEO transition effective September 2026 introduces leadership uncertainty
- Ongoing litigation costs (ARS Pharmaceuticals, Nemera) excluded from adjusted metrics but represent real cash outflow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000896622-26-000090 |
| Document: atr-20260430.htm | 0000896622-26-000090 |
| Document: 0000896622-26-000090-index-headers.html | 0000896622-26-000090 |
| Document: 0000896622-26-000090-index.html | 0000896622-26-000090 |
| Document: 0000896622-26-000090.txt | 0000896622-26-000090 |
| 8-K Data (Synthetic) | 0000896622-26-000090 |
Track record
12 reports on ATR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $143.86 Now $143.17 −0.48% settles Dec 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $137.20 Now $143.17 +4.35% settles Nov 30
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $126.55 Now $143.17 +13.13% settles Nov 20
- Sep 21, 20268w ago 8-K Bearish 4/10 Entry $125.45 to $125.77 Now $143.17 −14.13% ▼ −0.26% −0.81% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $128.31 to $121.16 Now $143.17 +11.58% ▼ −5.57% −4.45% vs SPY
- Sep 1, 202610w ago 8-K Neutral 2/10 Entry $130.92 to $121.44 Now $143.17 +9.36% ▼ −7.24% −8.42% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $135.78 to $128.31 Now $143.17 +5.44% ▼ −5.50% −6.10% vs SPY
- Aug 4, 202614w ago Insider Cluster Neutral 3/10 Entry $136.18 to $130.92 Now $143.17 +5.13% ▼ −3.86% −2.62% vs SPY
- Jul 17, 202617w ago Court Ruling Bullish 5/10 Entry $129.45 to $131.74 Now $143.17 +10.60% ▲ +1.77% −2.35% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 2/10 Entry $114.67 to $124.45 Now $143.17 +24.85% ▲ +8.53% +4.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers